乳腺癌的靶向治疗研究进展

被引：15

作者：

曾佳佳 ^{[1
,2
]}

杨润祥 ^{[1
]}

刘蓉 ^{[2
]}

机构：

[1] 昆明医科大学附属第三医院云南省肿瘤医院内二科

[2] 中国科学院昆明动物研究所动物模型与人类疾病机理重点实验室

来源：

中国生化药物杂志 | 2016年 / 36卷 / 01期

关键词：

乳腺癌; 靶向治疗; 乳腺癌干细胞;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

作为严重危害女性身心健康的恶性肿瘤,乳腺癌的发病率在我国女性恶性肿瘤中居首位。针对乳腺癌发生、发展有关的信号通路进行靶向药物的开发与临床应用成为乳腺癌治疗研究的新热点。本文主要介绍了目前针对各种分子分型的乳腺癌进行的临床靶向治疗和正在开展的靶向药物研发,同时对乳腺癌干细胞靶向治疗的最新进展进行综述。

引用

页码：7 / 11

页数：5

共 17 条

[1] Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? [J].

Anestis, Aristomenis ;

Karamouzis, Michalis V. ;

Dalagiorgou, Georgia ;

Papavassiliou, Athanasios G. .

CANCER TREATMENT REVIEWS, 2015, 41 (06) :547-553

[2] Cell cycle arrest and apoptogenic properties of opium alkaloids noscapine and papaverine on breast cancer stem cells [J].

Sajadian, Saharolsadat ;

Vatankhah, Melody ;

Majdzadeh, Maryam ;

Kouhsari, Shide Montaser ;

Ghahremani, Mohammad Hossein ;

Ostad, Seyed Nasser .

TOXICOLOGY MECHANISMS AND METHODS, 2015, 25 (05) :388-395

[3] Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer [J].

McNamara, Keely May ;

Yoda, Tomomi ;

Miki, Yasuhiro ;

Nakamura, Yasuhiro ;

Suzuki, Takashi ;

Nemoto, Noriko ;

Miyashita, Minoru ;

Nishimura, Reiki ;

Arima, Nobuyuki ;

Tamaki, Kentaro ;

Ishida, Takanori ;

Ohuchi, Noriaki ;

Sasano, Hironobu .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (02) :E184-E189

[4]

Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab[J] . Mehmet AN Sendur,Sercan Aksoy,Kadri Altundag.Future Oncol. . 2015 (1)

[5]

Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells[J] . Che-Hsin Lee,Yu-Ting Wu,Hung-Chun Hsieh,Yun Yu,Alice L. Yu,Wen-Wei Chang.Biochimie . 2014

[6] Breast cancer in China [J].

Fan, Lei ;

Strasser-Weippl, Kathrin ;

Li, Jun-Jie ;

St Louis, Jessica ;

Finkelstein, Dianne M. ;

Yu, Ke-Da ;

Chen, Wan-Qing ;

Shao, Zhi-Ming ;

Goss, Paul E. .

LANCET ONCOLOGY, 2014, 15 (07) :E279-E289

[7]

Treatment of HER2-positive breast cancer[J] . Maria Cristina Figueroa-Magalh?es,Danijela Jelovac,Roisin M. Connolly,Antonio C. Wolff.The Breast . 2013

[8]

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer[J] . Ayca Gucalp,Sara Tolaney,Steven J. Isakoff,James N. Ingle,Minetta C. Liu,Lisa A. Carey,Kimberly Blackwell,Hope Rugo,Lisle Nabell,Andres Forero,Vered Stearns,Ashley S. Doane,Michael Danso,Mary Ellen Moynahan,Lamia F. Momen,Joseph M. Gonzalez,Arooj Akhtar,Dilip D. Giri,Sujata Patil,Kimberly N. Feigin,Clifford A. Hudis,Tiffany A. Traina.Clinical Cancer Research . 2013

[9] Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells [J].

Qiu, Ming ;

Peng, Qinghai ;

Jiang, Ivy ;

Carroll, Christopher ;

Han, Guangzhou ;

Rymer, Isha ;

Lippincott, John ;

Zachwieja, Joseph ;

Gajiwala, Ketan ;

Kraynov, Eugenia ;

Thibault, Stephane ;

Stone, Donna ;

Gao, Yijie ;

Sofia, Susan ;

Gallo, Jorge ;

Li, Gang ;

Yang, Jennifer ;

Li, Kang ;

Wei, Ping .

CANCER LETTERS, 2013, 328 (02) :261-270

[10]

Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies[J] . Ryan P Roop,Cynthia X Ma.Future Oncol. . 2012 (3)

← 1 2 →